Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma
- 1 December 2017
- journal article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 154 (6) , 2092-2099.e2
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung AdenocarcinomaRadiology, 2016
- CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated AdenocarcinomaJournal of Thoracic Oncology, 2016
- Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypesEuropean Radiology, 2016
- CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the LungAmerican Journal of Roentgenology, 2015
- EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacityLung Cancer, 2015
- Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic SubtypesRadiology, 2013
- Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese PatientsJournal of Thoracic Oncology, 2013
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21Clinical Lung Cancer, 2006
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005